Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
March 15 2017 - 6:00AM
Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery
and development company advancing therapies for Duchenne muscular
dystrophy and Clostridium difficile infection, announces that Mr
Glyn Edwards, Chief Executive Officer, will present at the
Oppenheimer 27th Annual Healthcare Conference, 22 March 2017 at
2:10pm EDT in New York City.
A live audio webcast of the presentation will be
available through the Investors section on the Company’s website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit
Therapeutics Glyn Edwards / Richard Pye
(UK office)Erik Ostrowski / Michelle Avery (US office) |
Tel: +44 (0)1235 443
951 +1 617 225 4455 |
Cairn Financial
Advisers LLP (Nominated Adviser)Liam Murray / Tony
Rawlinson |
Tel: +44 (0)20 7213
0880 |
N+1
Singer (Broker)Aubrey Powell / Jen Boorer
|
Tel: +44 (0)20 7496
3000 |
MacDougall
Biomedical Communications (US media contact)Chris
Erdman / Karen Sharma |
Tel: +1 781 235 3060
cerdman@macbiocom.comksharma@macbiocom.com |
Consilium
Strategic Communications (Financial public relations,
UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey
Neville |
Tel: +44 (0)20 3709
5700summit@consilium-comms.com |
-END-
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Summit Therapeutics Plc (London Stock Exchange): 0 recent articles
More News Articles